Department of General Surgery (Hepatopancreatobiliary Surgery), The Affiliated Hospital, Southwest Medical University, Luzhou 646000, China.
Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, Department of General Surgery (Hepatopancreatobiliary surgery), The Affiliated Hospital, Southwest Medical University, Luzhou 646000, China.
Cell Signal. 2024 Nov;123:111338. doi: 10.1016/j.cellsig.2024.111338. Epub 2024 Aug 6.
PDAC, also known as pancreatic ductal adenocarcinoma, is often diagnosed at a late stage due to nonspecific symptoms and a distinct lack of reliable biomarkers for timely diagnosis. Ferroptosis, a novel non-apoptotic cell death mode discovered in recent years, is strongly linked to the progression of PDAC and the evasion of the immune system. The objective of this study is to discover a novel ceRNA biomarker associated with ferroptosis and investigate its possible molecular mechanisms and therapeutic potential in PDAC.
Based on the FerrDb and TCGA databases, the R survival package was used to screen for ferroptosis-related mRNAs associated with PDAC prognosis. The ferroptosis-related ceRNA network was identified by miRTarBase, miRNet, and starBase and visualized using Cytoscape. The LASSO regression analysis was used to build a risk model associated with ceRNA. Additionally, we investigated the correlation between the ceRNA axis and the infiltration of immune cells in PDAC by employing the ssGSEA algorithm. Spearman correlation analysis was used to investigate the association between the ceRNA network and the expression levels of immune checkpoint genes in PDAC. The prediction of potential medications for PAAD patients with high risk scores was conducted using the R package oncoPredict and the Genomics of Drug Sensitivity in Cancer (GDSC) repository. Expression levels of LINC02535 in clinical specimens and PDAC cell lines were determined using qRT-PCR. CCK-8, colony formation, EdU, wound healing, and transwell assays were performed to assess the impact of reducing LINC02535 on the growth, migration, and invasion of PDAC cell lines BxPC3 and PANC1.
We first discovered a new LINC02535/miR-30c-5p/EIF2S1 axis associated with ferroptosis and created a prognostic nomogram for predicting overall survival. Meanwhile, the risk scores of the LINC02535/miR-30c-5p/EIF2S1 axis associated with ferroptosis were linked to immune subtypes in PDAC. The high immune infiltration subtype exhibited elevated ceRNA risk scores and EIF2S1 expression. The correlation analysis revealed a positive correlation between ceRNA risk scores and four immune cells, namely Activated CD4 T cell, Memory B cell, Neutrophil, and Type 2 T helper cell, as well as four immune checkpoint genes, namely CD274, HAVCR2, PDCD1LG2, and TIGIT. The analysis of drug sensitivity indicated that individuals with a high-risk score may exhibit greater sensitivity to inhibitors targeting MEK1/2 compared to those with a low-risk score. In our validation experiments, it was observed that the expression of LINC02535 was increased in both PDAC tissues and cell lines. Additionally, the inhibition of LINC02535 resulted in decreased proliferation, migration, and invasion of PDAC cells. Rescue experiments demonstrated that LINC02535 promoted PDAC cell growth and metastasis by upregulating EIF2S1 expression.
To summarize, a novel ferroptosis-associated LINC02535/miR-30c-5p/EIF2S1 ceRNA network for PDAC patients was established. The analysis of this network's functionality offers potential insights for clinical decision-making and the advancement of precision medicine.
PDAC,也称为胰腺导管腺癌,由于其非特异性症状和缺乏可靠的生物标志物来进行及时诊断,通常在晚期才被诊断出来。铁死亡是近年来发现的一种新的非凋亡细胞死亡方式,与 PDAC 的进展和免疫系统的逃逸密切相关。本研究的目的是发现一种与铁死亡相关的新型 ceRNA 生物标志物,并探讨其在 PDAC 中的可能分子机制和治疗潜力。
基于 FerrDb 和 TCGA 数据库,使用 R survival 包筛选与 PDAC 预后相关的铁死亡相关 mRNAs。通过 miRTarBase、miRNet 和 starBase 识别铁死亡相关的 ceRNA 网络,并使用 Cytoscape 可视化。使用 LASSO 回归分析构建与 ceRNA 相关的风险模型。此外,我们通过 ssGSEA 算法研究了 ceRNA 轴与 PDAC 中免疫细胞浸润的相关性。采用 Spearman 相关分析研究了 ceRNA 网络与 PDAC 中免疫检查点基因表达之间的相关性。使用 R 包 oncoPredict 和 Genomics of Drug Sensitivity in Cancer (GDSC) 存储库对 PAAD 患者具有高风险评分的潜在药物进行预测。使用 qRT-PCR 检测临床标本和 PDAC 细胞系中的 LINC02535 表达水平。通过 CCK-8、集落形成、EdU、划痕愈合和 Transwell 实验评估降低 LINC02535 对 PDAC 细胞系 BxPC3 和 PANC1 生长、迁移和侵袭的影响。
我们首先发现了一个新的 LINC02535/miR-30c-5p/EIF2S1 轴与铁死亡相关,并为预测总体生存建立了一个预后列线图。同时,与铁死亡相关的 LINC02535/miR-30c-5p/EIF2S1 轴的风险评分与 PDAC 中的免疫亚型相关。铁死亡相关的 ceRNA 风险评分与四种免疫细胞(即活化的 CD4 T 细胞、记忆 B 细胞、中性粒细胞和 2 型 T 辅助细胞)以及四种免疫检查点基因(即 CD274、HAVCR2、PDCD1LG2 和 TIGIT)呈正相关。药物敏感性分析表明,高风险评分的个体可能对 MEK1/2 抑制剂的敏感性更高。在我们的验证实验中,观察到 LINC02535 在 PDAC 组织和细胞系中的表达增加。此外,抑制 LINC02535 导致 PDAC 细胞的增殖、迁移和侵袭减少。拯救实验表明,LINC02535 通过上调 EIF2S1 表达促进 PDAC 细胞的生长和转移。
总之,我们建立了一个用于 PDAC 患者的新型铁死亡相关 LINC02535/miR-30c-5p/EIF2S1 ceRNA 网络。对该网络功能的分析为临床决策制定和精准医学的发展提供了潜在的见解。